<?xml version="1.0" encoding="US-ASCII" ?>
<rss version="2.0">
<channel>
	<title>FDA Webview</title>
	<description>The leading publisher of FDA News, FDA Review, FDA Compliance, QSR News, and Food Drug Administration information since 1984.</description>
	<link>http://fdaweb.com/</link>
	<lastBuildDate>Thu, 13 Aug 2026 14:54:47 -0500</lastBuildDate>
	<item>
		<title>3 Observations on Reliance Life Sciences FDA-483</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161621</link>
		<description>FDA releases the Form FDA-483 issued following an inspection at India’s Reliance Life Sciences drug manufacturing facility in Navi Mumbai.</description>
		<pubDate>Thu, 13 Aug 2026 09:16:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161621</guid>
	</item>
	<item>
		<title>FDA Questions Zynlonta’s Benefit/Risk: Report</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161620</link>
		<description>FDA is raising questions about the risk/benefit of ADC Therapeutics’ Zynlonta as a second-line treatment for diffuse large B-cell lymphoma.</description>
		<pubDate>Thu, 13 Aug 2026 09:02:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161620</guid>
	</item>
	<item>
		<title>FDA Seeks Injunction Against Steiner Biotechnology</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161619</link>
		<description>The Department of Justice seeks an injunction to stop Steiner Biotechnology from manufacturing and marketing adulterated and misbranded dental medical devices that have been subject to FDA warnings for seven years.</description>
		<pubDate>Thu, 13 Aug 2026 06:59:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161619</guid>
	</item>
	<item>
		<title>FDA Guide Updates Procedures for Formal Drug/Biologic Meetings </title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161618</link>
		<description>FDA posts an updated guidance outlining procedures for formal meetings between the agency and sponsors or applicants developing or seeking approval for drugs and biological products.</description>
		<pubDate>Wed, 12 Aug 2026 11:31:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161618</guid>
	</item>
	<item>
		<title>Theresa Mullin Retires as CDER Associate Director</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161617</link>
		<description>CDER associate Center director for strategic initiatives Theresa Mullin retires after 28 years at the agency.</description>
		<pubDate>Wed, 12 Aug 2026 11:28:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161617</guid>
	</item>
	<item>
		<title>Lilly Files Six Lawsuits Over Illegal Retatrutide Sales</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161616</link>
		<description>Eli Lilly files six new lawsuits against U.S. entities it alleges are selling illegal, unapproved retatrutide products.</description>
		<pubDate>Wed, 12 Aug 2026 11:24:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161616</guid>
	</item>
	<item>
		<title>FDA Obstacles Lead to Overseas Trials: Survey</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161615</link>
		<description>A survey of 37 biotech executives shows FDA obstacles are sending more first-in-human trials overseas.</description>
		<pubDate>Wed, 12 Aug 2026 11:00:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161615</guid>
	</item>
	<item>
		<title>Use More Advisory Committee Temporary Voting Members: Column</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161614</link>
		<description>A Center for Medicine in the Public Interest opinion column calls on FDA to more aggressively recruit and use advisory committee temporary voting members.</description>
		<pubDate>Wed, 12 Aug 2026 10:50:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161614</guid>
	</item>
	<item>
		<title>Ban Infants’ Tylenol: Children’s Health Defense</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161613</link>
		<description>Children’s Health Defense petitions FDA to ban Infants’ Tylenol and place Boxed Warnings on labeling for some other Tylenol products.</description>
		<pubDate>Wed, 12 Aug 2026 10:02:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161613</guid>
	</item>
	<item>
		<title>FDA Expedited IND to Lean on Rolling Submissions/Reviews</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161612</link>
		<description>FDA officials detailing the agency’s new expedited IND pilot program say a central feature will be a rolling pre-IND submission process.</description>
		<pubDate>Wed, 12 Aug 2026 09:55:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161612</guid>
	</item>
	<item>
		<title>New Pathway Sought for Albuterol Inhalation Aerosol Products</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161611</link>
		<description>A petition submitted to FDA calls for the agency to create conditional nonprescription access to albuterol sulfate inhalers.</description>
		<pubDate>Tue, 11 Aug 2026 12:12:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161611</guid>
	</item>
	<item>
		<title>Belite Bio Files NDA for Stargardt Disease</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161610</link>
		<description>FDA accepts for priority review a Belite Bio NDA for tinlarebant for treating Stargardt Disease Type 1.</description>
		<pubDate>Tue, 11 Aug 2026 11:49:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161610</guid>
	</item>
	<item>
		<title>NDA for PTSD Therapy Resubmitted </title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161609</link>
		<description>Resilient Pharmaceuticals resubmits an NDA for its midomafetamine capsules for a proposed indication of treating post-traumatic stress disorder.</description>
		<pubDate>Tue, 11 Aug 2026 11:23:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161609</guid>
	</item>
	<item>
		<title>3 Observations in MSN Life Sciences Inspection</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161608</link>
		<description>FDA releases the Form FDA-483 with three observations from a 2024 inspection at India’s MSN Life Sciences Unit II active pharmaceutical ingredient manufacturing facility.</description>
		<pubDate>Tue, 11 Aug 2026 10:51:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161608</guid>
	</item>
	<item>
		<title>Hamilton Medical Removes Breathing Circuit Set</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161607</link>
		<description>An updated Class 1 recall notice says Hamilton Medical is recommending that certain coaxial breathing circuit sets used with HAMILTON-C1, HAMILTON T-1, and HAMILTON-MR1 ventilators be removed from where they are used or sold.</description>
		<pubDate>Tue, 11 Aug 2026 09:24:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161607</guid>
	</item>
	<item>
		<title>Aquestive Will Resubmit Anophylm NDA in 3rd Quarter</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161606</link>
		<description>Aquestive Therapeutics says that based on new human factor and pharmacokinetic trials of its Anophylm sought by FDA in a complete response letter, it plans to resubmit the Anophylm NDA in the third quarter of 2026, seeking an indication to treat type 1 allergic reactions. </description>
		<pubDate>Tue, 11 Aug 2026 08:47:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161606</guid>
	</item>
	<item>
		<title>Veloxis Paying $46 Million to Resolve Kickback Charges</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161605</link>
		<description>The Justice Department says it has reached a deferred prosecution agreement with Veloxis Pharmaceuticals under which the company is paying $46 million to resolve criminal and civil allegations that it paid kickbacks to induce prescriptions of its kidney transplant immunosuppressive drug Envarsus.</description>
		<pubDate>Tue, 11 Aug 2026 08:31:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161605</guid>
	</item>
	<item>
		<title>Tenax’s TNX-103 Misses Primary Endpoint in Phase 3 Trial</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161604</link>
		<description>Tenax Therapeutics says its oral levosimendan candidate TNX-103 failed to meet the primary endpoint in a Phase 3 trial evaluating the treatment in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction.</description>
		<pubDate>Mon, 10 Aug 2026 12:16:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161604</guid>
	</item>
	<item>
		<title>Trump Orders Changes to Childhood Vaccine Recommendations</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161603</link>
		<description>President Trump signs an executive order directing the federal government to develop what the White House calls &quot;Gold Standard Childhood Vaccine Recommendations,&quot; reducing the number of diseases for which routine childhood immunization is recommended.</description>
		<pubDate>Mon, 10 Aug 2026 11:12:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161603</guid>
	</item>
	<item>
		<title>Ibrahim Appointed CDER Deputy Center Director</title>
		<link>http://fdaweb.com/login.php?sa=v&amp;aid=D5161602</link>
		<description>FDA appoints Sarah Ibrahim as CDER deputy center director for Regulatory Programs, a role she has been serving in an acting capacity since January. </description>
		<pubDate>Mon, 10 Aug 2026 09:50:00 -0500</pubDate>
		<guid>http://fdaweb.com/login.php?sa=v&amp;aid=D5161602</guid>
	</item>
</channel>
</rss>